Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease.

Microbial cell factories - 7 Sept 2011

Yamaoka Masaru, Osawa Shin, Morinaga Tetsuro, Takenaka Shinji, Yoshida Ken-ichi

Abstract excerpt

BACKGROUND: A stereoisomer of inositol, scyllo-inositol, is known as a promising therapeutic agent for Alzheimer's disease, since it prevents the accumulation of beta-amyloid deposits, a hallmark of the disease. However, this compound is relatively rare in nature, whereas another stereoisomer of inositol, myo-inositol, is abundantly available. RESULTS: Bacillus subtilis possesses a unique inositol metabolism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Bacillus subtilis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Engineering

Share to Inositol

Share to Mutation

Share to Stereoisomerism

Source

Open in PubMed Open full text

Identifiers

PMID: 21896210
DOI: 10.1186/1475-2859-10-69
PMCID: PMC3176187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease.PMID 21896210Read ↗

Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.Semantic proximity Read ↗

The Inositol-3-Phosphate Synthase Biosynthetic Enzyme Has Distinct Catalytic and Metabolic Roles.Semantic proximity Read ↗

Structural investigation of myo-inositol dehydrogenase from Bacillus subtilis: implications for catalytic mechanism and inositol dehydrogenase subfamily classification.Semantic proximity Read ↗

Disruption of inositol biosynthesis through targeted mutagenesis in Dictyostelium discoideum: generation and characterization of inositol-auxotrophic mutants.Semantic proximity Read ↗

IpsA, a novel LacI-type regulator, is required for inositol-derived lipid formation in Corynebacteria and Mycobacteria.Semantic proximity Read ↗

Purification and biochemical characterization of Mycobacterium tuberculosis SuhB, an inositol monophosphatase involved in inositol biosynthesis.Semantic proximity Read ↗

The myo-inositol-1-phosphate synthase gene is essential in Trypanosoma brucei.Semantic proximity Read ↗

One-pot two-strain system based on glucaric acid biosensor for rapid screening of myo-inositol oxygenase mutations and glucaric acid production in recombinant cells.Semantic proximity Read ↗

Altering the Phosphorylation Position of Pyrophosphate-Dependent myo-Inositol-1-Kinase Based on Its Crystal Structure.Semantic proximity Read ↗

Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol.Semantic proximity Read ↗

Production and reutilization of an extracellular phosphatidylinositol catabolite, glycerophosphoinositol, by Saccharomyces cerevisiae.Semantic proximity Read ↗

myo-Inositol uptake is essential for bulk inositol phospholipid but not glycosylphosphatidylinositol synthesis in Trypanosoma brucei.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.